My Top 3 Healthcare Stocks to Buy in 2026

• With its divers merchandise line, AbbVie is simply a terrific dividend banal with a coagulated underlying business.

• Eli Lilly is increasing its apical enactment incredibly rapidly and expanding into different therapeutic areas.

• Intuitive Surgical's beardown moat and maturation prospects should let it to flooded challenges.

• 10 stocks we similar amended than AbbVie ›

After trailing broader equities implicit the past fewer years, volition the healthcare assemblage yet bounce backmost successful 2026? It's hard to foretell those things.

No substance what happens to the industry, though, determination are plentifulness of fantabulous healthcare stocks that look charismatic heading into the caller year. Let's see 3 that are among my favorites to buy: AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Intuitive Surgical (NASDAQ: ISRG).

One of AbbVie's biggest selling points is that it is simply a phenomenal banal for income seekers. The drugmaker has a uncommon progressive streak of 54 consecutive payout increases, which makes it a Dividend King. That's a radical of companies that person hiked their dividends for, astatine a minimum, 50 consecutive years. However, that means small unless a corp inactive has an underlying concern that is robust capable to make accordant revenue, earnings, and currency flow.

Thankfully, that's what we person with AbbVie. The institution continues to station results that lucifer what we expect from a beardown pharmaceutical giant. AbbVie's third-quarter gross came successful astatine $15.8 billion, 9% higher than the year-ago period.

The institution offered a scope of products that contributed to this performance: schizophrenia attraction Vraylar, Botox Therapeutics, migraine medicine Qulipta, and, of course, its astir important products stay Skyrizi and Rinvoq, 2 immunology medicines. These should proceed moving successful the close absorption adjacent twelvemonth -- and beyond, for that matter.

According to immoderate estimates, Skyrizi volition beryllium the 2nd best-selling cause successful the satellite by 2030 and make immoderate $26.6 cardinal successful sales, eclipsing the highest that AbbVie's erstwhile biggest maturation driver, Humira, ever reached. Rinvoq volition beryllium close extracurricular the apical 10.

In different words, AbbVie's prospects are attractive, particularly erstwhile considering the galore pipeline candidates and the imaginable to get caller ones done licensing deals oregon acquisitions. AbbVie's dividend way grounds and beardown concern marque it an fantabulous banal to buy.

Eli Lilly has been posting awesome maturation numbers lately. The company's third-quarter gross was $17.6 billion, up a ridiculous (by manufacture standards) 54% twelvemonth implicit year.